TikTok's claims about affordable semaglutide, fact-checked

What did @haleighweaver5 actually say?

She reported losing 30 pounds in roughly 3.5 to 4 months on compounded semaglutide or tirzepatide, then immediately walked it back: "just because I lost it in that amount of time does not mean you're going to lose it in that amount of time." She also noted that the first month involves a lower starting dose to let the body adjust. That's the full claim on the table, and it's more restrained than most GLP-1 content on TikTok.

She's not claiming a cure, not naming a dose, and not telling viewers they'll get the same result. For a 73K-view weight loss video, that's actually a decent baseline of honesty. The question is whether the numbers she's citing are grounded in real clinical data or just lucky anecdote.

Does the science back this up?

Mostly yes, but with important caveats. Losing 30 pounds in 4 months is on the faster end of what trials show, though not impossible depending on starting weight and which medication was used.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks. That's a much slower average pace than what she describes. However, SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide produced up to 22.5% body weight loss over 72 weeks, with heavier participants losing more in absolute pounds, especially early in treatment when caloric restriction effects are sharpest.

A person starting at 220 pounds could plausibly lose 30 pounds in 4 months if they respond strongly and modify eating behavior, but this would represent above-average response. The average is lower and slower. Her caveat about individual variation is doing real work here.

What did they get wrong (or right)?

She got the individual variation point right, and that matters more than people realize. GLP-1 response is genuinely heterogeneous. Some patients lose significant weight quickly; others see modest results or plateau early. Factors like baseline insulin resistance, gut hormone receptor sensitivity, and dietary behavior all influence outcomes in ways no TikTok video can account for.

Her description of the first month as a lower-dose adjustment period is also accurate. Both semaglutide and tirzepatide protocols typically involve dose escalation over weeks to months, starting low to reduce gastrointestinal side effects like nausea and vomiting, which affect a meaningful portion of users (reported in roughly 40-44% of participants in STEP and SURMOUNT trials).

What she doesn't address: the 30-pound figure is almost certainly not fat loss alone. Early GLP-1 weight loss includes water weight and glycogen depletion. She also doesn't mention that some of that loss could return if the medication is stopped, which long-term data consistently shows is a real risk (Wilding et al., 2022, Diabetes, Obesity and Metabolism).

What should you actually know?

GLP-1 medications produce real, clinically significant weight loss. The trial data is strong. But individual results vary widely, and the timeline this creator describes, 30 pounds in 4 months, sits at the optimistic end of the distribution rather than the middle.

A few things worth knowing before you benchmark your progress against a TikTok video:

• Average weekly weight loss in STEP 1 was closer to 0.5 to 1 pound per week after the first few weeks, not the pace implied by her result.
• Starting weight matters enormously. Someone losing 30 pounds from a starting weight of 250 pounds is on a different trajectory than someone starting at 180.
• Compounded semaglutide and tirzepatide are not FDA-approved drugs. They may contain the active ingredient in comparable amounts, but they are not bioequivalent to Wegovy, Ozempic, or Zepbound under FDA standards, and quality varies by compounding pharmacy.
• The dose escalation she mentions is standard practice and exists for a reason. Skipping it or rushing it increases side effect risk without improving outcomes.
• Weight regain after stopping GLP-1 therapy is well-documented. These are typically long-term medications, not short courses.